Cytosorbents Corp (CTSO) Files Form 4 Insider Buying : Michael G. Bator Buys 3,000 Shares

Cytosorbents Corp (CTSO): Michael G. Bator , director of Cytosorbents Corp purchased 3,000 shares on Jun 7, 2016. The Insider buying transaction was reported by the company on Jun 9, 2016 to the Securities and Exchange Commission. The shares were purchased at $4.88 per share for a total value of $14,640.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Jan 13, 2016, Investment Fund, Lp Njtc (10% owner) sold 124,281 shares at $4.27 per share price.On Dec 14, 2015, Kathleen P. Bloch (CFO) purchased 2,125 shares at $7.05 per share price.Also, On Nov 2, 2015, Vincent Capponi (Chief Operating Officer) sold 4,000 shares at $7.50 per share price.On Oct 19, 2015, Al Kraus (director) sold 6,774 shares at $6.22 per share price.

Cytosorbents Corp: On Thursday, Jun 9, 2016 heightened volatility was witnessed in Cytosorbents Corp which led to swings in the share price. The shares opened for trading at $4.5 and hit $4.72 on the upside , eventually ending the session at $4.57, with a gain of 1.56% or 0.07 points. The heightened volatility saw the trading volume jump to 55,949 shares. The 52-week high of the share price is $8.1 and the company has a market cap of $116 M . The 52-week low of the share price is at $3.11.

Cytosorbents Corp Money Flow Index Chart

Company has been under the radar of several Street Analysts.Cytosorbents Corp is Initiated by Maxim Group to Buy and the brokerage firm has set the Price Target at $8. The Rating was issued on May 24, 2016.

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company utilizes blood purification to modulate inflammation for treating multiple organ failure illnesses and cardiac surgery. The Company’s purification technologies are based on biocompatible porous polymer beads that can remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company’s product CytoSorb is approved in the European Union as an extracorporeal cytokine filter designed to reduce the cytokine storm that could cause inflammation organ failure and death in common critical illnesses such as sepsis burn injury trauma lung injury and pancreatitis. The Company also has other products under development based upon its blood purification technology including HemoDefend ContrastSorb DrugSorb BetaSorb and others. In addition CytoSorb can be used in conditions such as cardiac surgery autoimmune disease flares among others.

Leave a Reply

Cytosorbents Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Cytosorbents Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.